drugset / Trial / NCT00575016

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

NCT00575016 ↗

Phase 2 Terminated 74 enrolled Allergan
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to explore the effectiveness and safety of several doses of botulinum toxin type A in treating overactive bladder in patients with spinal cord injury.

Timeline

Start
2007-12
Primary completion
2010-02
Completion
2010-07

Outcome

Outcome not reported

Stopped (Enrollment): “The study was terminated early due to enrollment challenges.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 200 iu Other

Indications